Physician profile
Kristen M Vallery
NPI 1508811274
$3,581.07
in general payments reported to CMS, 2019-2025
43 companies · $687 in 2025
The $687 reported for 2025 was more than what 87% of Obstetrics providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,019 · 2020: $208 · 2021: $372 · 2022: $375 · 2023: $193 · 2024: $727 · 2025: $687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,532 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,532.46 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $540.55 | 2024-2025 | Zurzuvae, Vumerity |
| Abbvie INC. | $468.30 | 2019-2025 | |
| Exeltis, USA INC. | $277.84 | 2019-2025 | Slynd |
| Pfizer INC. | $254.19 | 2019-2024 | |
| Astellas Pharma US INC | $217.42 | 2019-2025 | Veozah |
| Organon LLC | $164.56 | 2021-2025 | Nexplanon |
| Shield Therapeutics INC | $133.17 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $118.80 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $112.13 | 2024-2025 | Myfembree |
| Merck Sharp & Dohme LLC | $103.94 | 2019-2021 | |
| Therapeuticsmd, INC. | $81.73 | 2019-2020 | |
| Avion Pharmaceuticals | $81.39 | 2019-2020 | |
| Millicent US INC | $80.41 | 2019-2025 | Intrarosa, Femlyv |
| Amag Pharmaceuticals, INC. | $77.41 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $73.96 | 2019 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Vallery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.